

Medincell to Join the Euronext SBF 120 Index

Medincell joins the Euronext SBF 120 index, which includes the 120 largest companies listed on Euronext Paris, including the CAC 40 and most of the key players in the French economy. Medincell joins also the CAC Mid 60 index.

Christophe Douat, CEO of Medincell, said: *“Just six years after our IPO, Medincell joins the SBF 120, a recognition of our strength and performance. This milestone enhances our attractiveness to new French and international institutional investors and will increase our visibility among financial analysts and the media. This distinction should lead to greater trading volume in our shares. I would like to thank Medincell’s employees - who are all shareholders, and all our individual and institutional shareholders for their confidence. This new step is the result of their ongoing support.”*

The composition of the SBF 120 and CAC Mid 60 is decided by Euronext’s Scientific Council for Indices on the basis of the market capitalizations and liquidity (trading volume) of companies listed on Euronext Paris.

Medincell’s inclusion in the index will be effective from 20 December, after market close.

The SBF 120 index includes the following companies listed on Euronext Paris:

- CAC 40: the 40 largest market capitalizations
<https://live.euronext.com/fr/product/indices/FR0003500008-XPAP>
- CAC Next 20: The next 20 largest stocks following the CAC 40. Together, the CAC 40 and CAC Next 20 form the CAC Large 60.
<https://live.euronext.com/fr/product/indices/QS0010989109-XPAP>
- CAC Mid 60: the 60 largest capitalizations on the first and second markets (excluding the CAC Large 60)
<https://live.euronext.com/fr/product/indices/QS0010989117-XPAP>

List of companies in the SBF 120 index: <https://live.euronext.com/fr/product/indices/FR0003999481-XPAP>

List of companies in the CAC Mid 60 index: <https://live.euronext.com/fr/product/indices/QS0010989117-XPAP>

Euronext press release: <https://www.euronext.com/en/about/media/euronext-press-releases/euronext-announces-december-2024-quarterly-review-results-cacr>

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals

medincell.com

Contacts

David Heuzé

Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim

Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé

Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier

Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94